Has Marion Tamesis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,238 in general payments to Marion Tamesis, MD across 236 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marion Tamesis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marion Tamesis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marion Tamesis, MD

Dermatology · Johnson City, NYNPI 1821022344

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,515, 6.0 times the $252 reported in 2019.

$5,238in general payments, 2019–2025

Across 236 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$696
Pfizer$675
Novartis$601
Johnson & Johnson$508
Sanofi$454
Lilly USA, LLC$435
plus $2K from 17 others

What the payments were for

Food & beverage$5,12998%
Education$1092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	40	$696
Pfizer	30	$675
Novartis	38	$601
Johnson & Johnson	23	$508
Sanofi	20	$454
Lilly USA, LLC	19	$435
Incyte Corporation	18	$429
Regeneron Healthcare Solutions, Inc.	7	$275
E.r. Squibb & Sons, L.L.C.	7	$248
Amgen	7	$154
Stemline Therapeutics Inc.	1	$139
Sun Pharmaceutical Industries Inc.	6	$119
Boehringer Ingelheim	5	$97
Genentech USA, Inc.	1	$97
Organogenesis Inc.	2	$67
UCB, Inc.	2	$53
Galderma Laboratories, L.p.	3	$51
Biofrontera Inc.	2	$49
Xeris Pharmaceuticals, Inc.	1	$22
Bristol Myers Squibb	1	$21
Botanix SB Inc	1	$17
Helsinn Therapeutics (U.S.), Inc.	1	$16
Arcutis Biotherapeutics, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,238 in reported general payments places this provider in the 60th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York →

Medicare billing

Part B allowed, 2024

$183,616

Medicare patients

424

Services billed

2,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	12	$51,967
Clobetasol Propionate	145	$4,860
Fluorouracil	30	$1,983
Imiquimod	32	$1,913
Metronidazole	29	$1,646
Ketoconazole	66	$1,237
Econazole Nitrate	36	$1,232
Dutasteride	59	$1,164
Clindamycin Phosphate	26	$1,069
Triamcinolone Acetonide	135	$1,031
Mycophenolate Mofetil	11	$599
Mupirocin	79	$514
Doxycycline Hyclate	52	$398
Hydroxyzine Hcl	32	$343
Hydrocortisone	17	$74

Paid to pharmacies, not to this prescriber.

Other dermatology in Johnson City

Alexandra GolantNew York$3.6M
David CohenNew York$3M
Michael CameronNew York$2.6M
Saakshi KhattriNew York$2.4M
Amy WechslerNew York$2.4M
Jeffrey WeinbergKew Gardens$2.3M
Joshua ZeichnerNew York$2.1M
Russell CohenOceanside$2.1M
Jeffrey LaducaAuburn$1.9M
Emma GuttmanNew York$1.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →